-
EP4061372
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4061372
| EP4061372 - METHODS OF TREATING SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 24.05.2024 Database last updated on 21.03.2026 | |
| Former | Request for examination was made Status updated on 26.08.2022 | ||
| Former | The international publication has been made Status updated on 29.05.2021 | ||
| Former | unknown Status updated on 08.06.2020 | Most recent event Tooltip | 28.05.2025 | New entry: Renewal fee paid | Applicant(s) | For all designated states Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | [2022/39] | Inventor(s) | 01 /
CALVO, Pilar c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 02 /
KAHATT, Carmen c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 03 /
FERNANDEZ, José María c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 04 /
TOBIO, Maria c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 05 /
FUDIO, Salvador c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 06 /
SOTO, Arturo c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 07 /
LARDELLI, Pilar c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 08 /
FERNANDEZ, Cristian c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 09 /
ZARZUELO ALBA, Maria Del Mar c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 10 /
POLANCO NOAIN, María de la Concepción c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 11 /
MANZANARO LÓPEZ, Sonia c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | 12 /
VELASCO, Honorio c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES | [2022/39] | Representative(s) | Gurney, Steven Evolve Intellectual Property Limited Nine Hills Road Cambridge CB2 1GE / GB | [N/P] |
| Former [2022/39] | Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | Application number, filing date | 20729071.9 | 29.05.2020 | [2022/39] | WO2020EP65093 | Priority number, date | EP20190383025 | 21.11.2019 Original published format: EP 19383025 | EP20200382409 | 14.05.2020 Original published format: EP 20382409 | WO2020EP63734 | 15.05.2020 Original published format: PCT/EP2020/063734 | [2022/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021098992 | Date: | 27.05.2021 | Language: | EN | [2021/21] | Type: | A1 Application with search report | No.: | EP4061372 | Date: | 28.09.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.05.2021 takes the place of the publication of the European patent application. | [2022/39] | Search report(s) | International search report - published on: | EP | 27.05.2021 | Classification | IPC: | A61K31/4995, A61P35/00 | [2022/39] | CPC: |
A61K31/4995 (EP,CN,IL,KR,US);
A61K31/4738 (IL,US);
A61K9/19 (CN,IL,KR);
A61K31/4745 (IL,KR,US);
A61K31/573 (IL,KR,US);
A61K38/193 (IL,US);
A61K45/06 (IL,KR);
A61K47/12 (CN,IL,KR);
A61K47/26 (CN,IL,KR);
A61K9/0019 (CN,IL,US);
A61P11/00 (CN,IL,US);
A61P35/00 (EP,CN,IL,KR,US);
C07D515/22 (IL,KR);
C07D519/00 (IL,US);
A61K2300/00 (IL,KR);
C07B2200/13 (IL,KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/39] | Extension states | BA | 14.06.2022 | ME | 14.06.2022 | Validation states | KH | 14.06.2022 | MD | 14.06.2022 | TN | 14.06.2022 | Title | German: | VERFAHREN ZUR BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS MIT LURBINECTEDINFORMULIERUNGEN | [2022/39] | English: | METHODS OF TREATING SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS | [2022/39] | French: | PROCÉDÉS DE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES AVEC DES FORMULATIONS DE LURBINECTÉDINE | [2022/39] | Entry into regional phase | 14.06.2022 | National basic fee paid | 14.06.2022 | Designation fee(s) paid | 14.06.2022 | Examination fee paid | Examination procedure | 14.06.2022 | Examination requested [2022/39] | 14.06.2022 | Date on which the examining division has become responsible | 10.01.2023 | Amendment by applicant (claims and/or description) | 24.05.2024 | Despatch of a communication from the examining division (Time limit: M06) | 25.11.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 14.06.2022 | Renewal fee patent year 03 | 30.05.2023 | Renewal fee patent year 04 | 28.05.2024 | Renewal fee patent year 05 | 27.05.2025 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] WO2012062920 (PHARMA MAR SA et al.) | [XP] WO03014127 (PHARMA MAR SA et al.) | [X] WO2011147828 (PHARMA MAR SA et al.) [X] 4,21-26,28,30 * the whole document * * examples 10,17-19 * | [X] MATT L. HARLOW ET AL: "Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus", CANCER RESEARCH, vol. 76, no. 22, 3 October 2016 (2016-10-03), US, pages 6657 - 6668, XP055733038, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-16-0568 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-16-0568 | [X] RYOKO TAKAHASHI ET AL: "Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary", PLOS ONE, vol. 11, no. 3, 17 March 2016 (2016-03-17), pages e0151050, XP055733041, DOI: 10.1371/journal.pone.0151050 [X] 4 DOI: http://dx.doi.org/10.1371/journal.pone.0151050 | [X] ANNA F FARAGO ET AL: "ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line", FUTURE ONCOLOGY, vol. 15, no. 3, 1 January 2019 (2019-01-01), GB, pages 231 - 239, XP055733050, ISSN: 1479-6694, DOI: 10.2217/fon-2018-0597 [X] 4 DOI: http://dx.doi.org/10.2217/fon-2018-0597 | [X] WEIMING HE ET AL: "A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin", ANGEWANDTE CHEMIE, vol. 58, no. 12, 18 March 2019 (2019-03-18), DE, pages 3972 - 3975, XP055733376, ISSN: 1433-7851, DOI: 10.1002/anie.201900035 [X] 4 DOI: http://dx.doi.org/10.1002/anie.201900035 | [X] JIMENO ANTONIO ET AL: "Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly x 2 every-3-week schedule", INVESTIGATION NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 35, no. 4, 20 January 2017 (2017-01-20), pages 471 - 477, XP036272957, ISSN: 0167-6997, [retrieved on 20170120], DOI: 10.1007/S10637-017-0427-2 [X] 4,7,8,10,12,21-26,28,30 * the whole document * DOI: http://dx.doi.org/10.1007/s10637-017-0427-2 | [X] DIEGO KAUFFMANN-GUERRERO ET AL: "Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin", LUNG CANCER: TARGETS AND THERAPY, vol. Volume 11, 1 March 2020 (2020-03-01), pages 27 - 31, XP055733044, DOI: 10.2147/LCTT.S239223 [X] 4,8,10 * the whole document * * figures 2-4 * DOI: http://dx.doi.org/10.2147/LCTT.S239223 | [X] COTE GREGORY M ET AL: "A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 126, 31 December 2019 (2019-12-31), pages 21 - 32, XP086014112, ISSN: 0959-8049, [retrieved on 20191231], DOI: 10.1016/J.EJCA.2019.10.021 [X] 2,16,20-30 * the whole document * DOI: http://dx.doi.org/10.1016/j.ejca.2019.10.021 | [XD] M. E. ELEZ ET AL: "First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 20, no. 8, 15 April 2014 (2014-04-15), US, pages 2205 - 2214, XP055733302, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-1880 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-13-1880 | [X] PAZ-ARES LUIS ET AL: "Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors", INVESTIGATION NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 35, no. 2, 21 November 2016 (2016-11-21), pages 198 - 206, XP036190279, ISSN: 0167-6997, [retrieved on 20161121], DOI: 10.1007/S10637-016-0410-3 [X] 21-30 * the whole document * * scheme 3 * DOI: http://dx.doi.org/10.1007/s10637-016-0410-3 | Examination | M. E. ELEZ ET AL: "First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 20, no. 8, 15 April 2014 (2014-04-15), US, pages 2205 - 2214, XP055733302, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-1880 [A] 1-30 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-13-1880 | by applicant | US7763615 | WO03014127 |